造血干细胞移植后侵袭性真菌感染的危险因素:系统综述与荟萃分析
该系统综述与荟萃分析纳入51项研究共109155例造血干细胞移植患者,其中45项研究提供足够数据进行荟萃分析,旨在明确移植后侵袭性真菌感染的危险因素。结果显示长期中性粒细胞减少、强化移植物抗宿主病治疗、既往移植、既往确诊或临床诊断侵袭性真菌感染、急性移植物抗宿主病≥II级、广泛或重度慢性移植物抗宿主病、移植期间使用抗胸腺细胞球蛋白、单倍体移植、高剂量糖皮质激素、EB病毒感染、巨细胞病毒感染或再激活及低白蛋白为危险因素,抗真菌预防是唯一保护因素。
要点
- 长期中性粒细胞减少、强化移植物抗宿主病治疗、既往移植和既往侵袭性真菌感染是移植后侵袭性真菌感染的危险因素。
- 急性移植物抗宿主病≥II级、广泛或重度慢性移植物抗宿主病、移植期间使用抗胸腺细胞球蛋白、单倍体移植和高剂量糖皮质激素为危险因素。
- EB病毒感染、巨细胞病毒感染或再激活及低白蛋白为危险因素,抗真菌预防是唯一保护因素。
核心结论
- 该荟萃分析全面综述了造血干细胞移植后侵袭性真菌感染的危险因素,所获见解有助于对侵袭性真菌感染高风险患者进行分层并促进抗真菌预防策略。
研究设计与样本
- 系统综述与荟萃分析,检索Pubmed、EMBASE、Web of Science和Cochrane Library截至2023年4月,纳入评估造血干细胞移植受者侵袭性真菌感染危险因素的病例对照或队列研究。
- 共筛选1637项研究,纳入51项研究涉及109155例患者,其中45项研究提供足够数据进行荟萃分析。
- 采用RevMan 5.4和R语言4.1.2进行荟萃分析,使用Mantel-Haenszel法的随机效应模型合并原始研究结果。
- 侵袭性真菌感染根据欧洲癌症研究与治疗组织/真菌研究组(EORTC/MSG)标准或类似定义进行定义。
- 使用改良版纽卡斯尔-渥太华量表评估偏倚风险。
主要发现
- 侵袭性真菌感染的危险因素包括长期中性粒细胞减少、强化移植物抗宿主病治疗、既往移植、既往确诊或临床诊断侵袭性真菌感染、急性移植物抗宿主病≥II级、广泛或重度慢性移植物抗宿主病、移植期间使用抗胸腺细胞球蛋白、单倍体移植、高剂量糖皮质激素、EB病毒感染、巨细胞病毒感染或再激活及低白蛋白。
- 抗真菌预防是唯一的保护因素。
- 对于侵袭性曲霉病或侵袭性霉菌感染,最主要的危险因素为广泛或重度慢性移植物抗宿主病、呼吸道病毒感染、高剂量糖皮质激素、急性移植物抗宿主病≥II级和人类白细胞抗原错配。
- 脐血移植是侵袭性念珠菌病唯一的显著危险因素。
- 各种危险因素之间可能存在高度相互依赖性。
关键数值与推荐
- 侵袭性真菌感染根据EORTC/MSG标准或类似定义进行定义。
- 使用改良版纽卡斯尔-渥太华量表评估偏倚风险。
- 采用Mantel-Haenszel法的随机效应模型合并原始研究结果。
临床怎么用
- 所获见解可帮助对侵袭性真菌感染高风险患者进行分层并促进抗真菌预防策略。
局限性
- 各种危险因素之间可能存在高度相互依赖性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive fungal infections (IFIs) are common infectious complications after haematopoietic stem cell transplantation (HSCT), seriously threatening the survival of patients. OBJECTIVES: This systematic review aimed to investigate risk factors associated with IFIs following HSCT. METHODS: Two authors independently conducted the selection of studies and extraction of data. Risk factors for IFIs, invasive aspergillosis or invasive mould infections and invasive candida infection after HSCT were compiled separately by meta-analysis using RevMan 5.4 and R language 4.1.2. DATA SOURCES: Pubmed, EMBASE, Web of Science, and the Cochrane Library until April 2023. STUDY ELIGIBILITY CRITERIA: Case-control or cohort studies that assessed risk factors for IFIs among HSCT recipients were included. PARTICIPANTS: Patients experiencing HSCT. TEST/S: None. REFERENCE STANDARD: The IFIs were defined according to the European Organisation for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria, or a similar definition. ASSESSMENT OF RISK OF BIAS: A modified version of the Newcastle-Ottawa Scale was used. METHODS OF DATA SYNTHESIS: A random-effects model with the Mantel-Haenszel method was used to pool results from primary studies. RESULTS: Out of 1637 studies screened, 51 studies involving 109 155 patients were included, with 45 studies providing adequate data for meta-analysis. Identified risk factors for IFIs included prolonged neutropenia, intensified therapy for graft-versus-host disease (GVHD), previous transplantation, previous proven or probable IFI, acute GVHD ≥ grade II, extensive or severe chronic GVHD, use of anti-thymocyte globulin during transplantation, haploidentical transplantation, high-dose glucocorticoids, Epstein-Barr virus infection, cytomegalovirus infection or reactivation, and lower albumin. Conversely, antifungal prophylaxis emerged as the sole preventive factor. For invasive aspergillosis or invasive mould infections, the top risk factors were extensive or severe chronic GVHD, respiratory viral infection, high-dose glucocorticoids, acute GVHD ≥ grade II, and human leukocyte antigen mismatch. Cord blood transplantation was the sole significant risk factor for invasive candidiasis. However, there was likely a high degree of interdependence among various risk factors. DISCUSSION: This meta-analysis provides a thorough review of risk factors for IFIs infection after HSCT. The achieved insights can aid in stratifying patients who are at an elevated risk of IFIs and promoting antifungal preventive strategies.
引用
- Biyun L, Yahui H, Yuanfang L, et al. Risk factors for invasive fungal infections after haematopoietic stem cell transplantation: a systematic review and meta-analysis. Clin Microbiol Infect. 2024. PMID: 38280518. doi:10.1016/j.cmi.2024.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。